The first nonstimulant ADHD medication approved by the FDA for adult use in two decades, Qelbree (Viloxazine) achieved positive results in a randomized, double-blind, placebo-controlled Phase 3 study.
for adults have been very limited,” said Greg Mattingly, M.D., founding partner of St. Charles Psychiatric Associates, in a statement. “This approval is positive news and offers a new novel option for the millions of American adults who are trying to find the right treatment to manage their ADHD symptoms.
The once-daily, flexible-dose nonstimulant ADHD drug medication belongs to the selective norepinephrine reuptake inhibitor group of medicines. Safety information may be found at
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
PMS and ADHD: How the Menstrual Cycle Intensifies Symptoms“As an OB-GYN nurse, I can tell you that when progesterone levels are high, dopamine levels drop. So, for women with ADHD, the week leading up to menstruation is an awful time to try and get anything done.”
Read more »
FDA Officials Say Annual Covid-19 Shots May Be Needed In The FutureThe United States might need to update its Covid-19 vaccines each year, according to a trio of top US Food and Drug Administration officials, and 'a new normal' may include an annual Covid-19 vaccine alongside a seasonal flu shot.
Read more »
FDA Warns of Counterfeit Home COVID Test KitsThe FDA warns Americans to watch out for phony at-home, over-the-counter COVID tests that look a lot like the real things.
Read more »
So, There’s Lead In Your Juice—and the FDA Is Trying to Lower the AmountHow it got there in the first place is even more interesting.
Read more »
Vaxxinity vaccine to treat Alzheimer’s wins FDA fast-track designationMultiple vaccines in the Dallas biotech company’s platform made significant regulatory progress in the last month.
Read more »
FDA Rejects Two Proposed Cancer Drugs Developed in ChinaThe Food and Drug Administration rejected two proposed cancer drugs that were developed in China, underscoring a tougher U.S. regulatory stance toward such drugs
Read more »